利拉鲁肽联合门冬胰岛素治疗难治性2型糖尿病的疗效

Efficacy of Liraglutide and Insulin Aspart in the Treatment of Refractory Type 2 Diabetes

目的探讨利拉鲁肽、门冬胰岛素治疗难治性2型糖尿病的疗效。方法选取葫芦岛市中心医院收治的难治性2型糖尿病患者114例为研究对象,随机分为研究组(利拉鲁肽联合门冬胰岛素)与对照组(门冬胰岛素)各57例,比较两组患者的治疗效果。结果治疗后与对照组相比较,研究组空腹血糖、餐后2 h血糖、糖化血红蛋白低,胰岛素使用剂量少,差异均有统计学意义(均P<0.05);研究组有效率(96.49%)较对照组(85.96%)高,研究组不良反应(5.26%)较对照组(19.29%)低,差异均有统计学意义(均P<0.05)。结论对难治性2型糖尿病患者采用门冬胰岛素联合利拉鲁肽治疗临床疗效显著,能有效控制血糖,减少胰岛素使用量,且安全性较高。

Objective To explore the efficacy of liraglutide and insulin aspart in the treatment of refractory type 2 diabetes mellitus.Methods A total of 114 patients with refractory type 2 diabetes mellitus admitted to Huludao Central Hospital were selected as study subjects and randomly divided into study group(liraglutide combined with insulin aspart)and control group(insulin aspart),with 57 cases in each group.The therapeutic effects of the 2 groups were compared.Results Compared with the control group after the treatment,the fasting blood glucose,postprandial 2-hour blood glucose and glycosylated hemoglobin in the study group were lower,and the dosage of insulin was less,with statistically significant difference(P<0.05);the effective rate of the study group(96.49%)was higher than that of the control group(85.96%);the adverse reactions of the study group(5.26%)were lower than that of the control group(19.29%)and the difference was statistically significant(P<0.05).Conclusion The combination of insulin aspart and liraglutide is significantly effective in the treatment of patients with refractory type 2 diabetes mellitus.It can effectively control blood sugar,reduce insulin use and has high safety.